CN113813359A - 益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 - Google Patents
益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 Download PDFInfo
- Publication number
- CN113813359A CN113813359A CN202110986029.1A CN202110986029A CN113813359A CN 113813359 A CN113813359 A CN 113813359A CN 202110986029 A CN202110986029 A CN 202110986029A CN 113813359 A CN113813359 A CN 113813359A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- peptide
- lymph
- chinese medicine
- arthralgia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 41
- 206010027599 migraine Diseases 0.000 title claims abstract description 40
- 208000006820 Arthralgia Diseases 0.000 title claims abstract description 26
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 18
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 18
- 210000002751 lymph Anatomy 0.000 title claims abstract description 14
- 238000005516 engineering process Methods 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000003910 polypeptide antibiotic agent Substances 0.000 title description 4
- 239000000463 material Substances 0.000 claims abstract description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 51
- 239000000341 volatile oil Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000013271 transdermal drug delivery Methods 0.000 claims abstract description 20
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 15
- 235000018291 probiotics Nutrition 0.000 claims abstract description 15
- 230000000529 probiotic effect Effects 0.000 claims abstract description 14
- 230000017531 blood circulation Effects 0.000 claims abstract description 13
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 9
- 230000003467 diminishing effect Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001467 acupuncture Methods 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 5
- 206010010774 Constipation Diseases 0.000 claims abstract description 4
- 208000004232 Enteritis Diseases 0.000 claims abstract description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims abstract description 4
- 230000004151 fermentation Effects 0.000 claims abstract description 4
- 229940116269 uric acid Drugs 0.000 claims abstract description 4
- 208000007882 Gastritis Diseases 0.000 claims abstract description 3
- 244000005700 microbiome Species 0.000 claims abstract description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims abstract 2
- 208000019206 urinary tract infection Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 70
- 210000001165 lymph node Anatomy 0.000 claims description 52
- 239000000284 extract Substances 0.000 claims description 45
- 239000000686 essence Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 15
- 230000005906 menstruation Effects 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 210000002435 tendon Anatomy 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- 244000061520 Angelica archangelica Species 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 6
- 244000179560 Prunella vulgaris Species 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 241000220317 Rosa Species 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000000552 rheumatic effect Effects 0.000 claims description 6
- 230000037317 transdermal delivery Effects 0.000 claims description 6
- 241000194108 Bacillus licheniformis Species 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims description 5
- 241000913745 Spatholobus Species 0.000 claims description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 5
- 235000011477 liquorice Nutrition 0.000 claims description 5
- 241000205585 Aquilegia canadensis Species 0.000 claims description 4
- 240000005528 Arctium lappa Species 0.000 claims description 4
- 235000003130 Arctium lappa Nutrition 0.000 claims description 4
- 235000008078 Arctium minus Nutrition 0.000 claims description 4
- 244000020518 Carthamus tinctorius Species 0.000 claims description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 241000195954 Lycopodium clavatum Species 0.000 claims description 4
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 4
- 244000046146 Pueraria lobata Species 0.000 claims description 4
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 4
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 4
- 244000042430 Rhodiola rosea Species 0.000 claims description 4
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 235000008113 selfheal Nutrition 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 206010007247 Carbuncle Diseases 0.000 claims description 3
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 206010017553 Furuncle Diseases 0.000 claims description 3
- 208000003351 Melanosis Diseases 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- 210000001015 abdomen Anatomy 0.000 claims description 3
- 239000002390 adhesive tape Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 230000002439 hemostatic effect Effects 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 2
- 230000001050 lubricating effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims 2
- 235000008216 herbs Nutrition 0.000 claims 2
- 241000555682 Forsythia x intermedia Species 0.000 claims 1
- 240000001949 Taraxacum officinale Species 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 206010000059 abdominal discomfort Diseases 0.000 abstract 1
- 230000002175 menstrual effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 9
- 210000003739 neck Anatomy 0.000 description 9
- 230000002040 relaxant effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000002199 base oil Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229940060184 oil ingredients Drugs 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 241000244365 Ligusticum sinense Species 0.000 description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 4
- 229940067866 dandelion extract Drugs 0.000 description 4
- 235000020691 dandelion extract Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000001845 taraxacum officinale leaf extract Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000245665 Taraxacum Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000555712 Forsythia Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 229940063333 burdock root extract Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002607 contrast-enhanced ultrasound Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 229940002508 ginger extract Drugs 0.000 description 2
- 235000020708 ginger extract Nutrition 0.000 description 2
- 239000008169 grapeseed oil Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000351595 Azolla imbricata Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- -1 Ca2+ ion Chemical class 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000005819 Magnolia denudata Species 0.000 description 1
- 235000016094 Magnolia denudata Nutrition 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000009277 Panax notoginseng extract Substances 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 1
- 206010054088 Urinary tract infection bacterial Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- DEDOPGXGGQYYMW-UHFFFAOYSA-N molinate Chemical compound CCSC(=O)N1CCCCCC1 DEDOPGXGGQYYMW-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 238000003062 neural network model Methods 0.000 description 1
- 206010065988 nodular fasciitis Diseases 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 201000006081 pseudosarcomatous fibromatosis Diseases 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000007930 transdermal spray Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008832 zhongfu Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
本发明一种益菌药肽透皮给药,通过按摩经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经的技术与产品制备,包括主料、辅料配制益菌药肽及透皮给药的按摩方法。主料包括17味中药,可单独或复合使用,形成通用型、益目型、妇科型和清火型配组,也可以根据要求加入其他中药,这些中药用微生物分别或者组合发酵,用精油、水及酒精等三种方法提取后,与辅料分为精油类和水溶精华液类按一定比例配成益菌药肽精华,按摩推拿3条穴位和淋巴走向治疗偏头痛,按摩关节及体表结节点相关穴位以干预治疗。产品可以制备成液体涂用或者贴式。益菌药肽发酵物还可以治疗肠胃不适、胃炎、肠炎、便秘、尿酸、尿路感染和细菌性阴道炎等。
Description
技术领域
本发明涉及一种益菌发酵中药和肽的提取物透皮给药疏通经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经的技术与产品制备方法,属于应用生物技术领域。
背景技术
偏头痛(migraine)、关节痛(arthralgia)是最常见的病痛。尤其是偏头痛是临床最常见的原发性头痛类型,偏头痛的发病机制尚不十分清楚,一般持续4~72小时,广泛存在于各类人群中,包括儿童、青年、中年和老年,尤其是有学习、工作、生活压力的以及亚健康状态的人群中。甚至部分高原驻训部队官兵也因环境与低氧常常头痛,并伴有淋巴结肿大等【1】。感染也会导致偏头痛,是致病微生物引起的急慢性炎症,如细菌【2】、病毒【3,4】、立克次体等引起如急性蜂窝组织炎、化脓性扁桃体炎、牙龈炎、传染性单核细胞增多症、恙虫病、结核【5】等,能够引起明显的淋巴结结节【2-5】。
淋巴结包括浅表淋巴结和深部淋巴结分布全身,常呈0.2~0.5cm组群分布,约有600-700个,对于机体抵抗外来细菌、病毒等病原体感染有着非常重要的作用。浅表淋巴结是指用手可以触摸到的、在机体较浅表位置的淋巴结,常分布于颈部、颌下、腋下、腹股沟区。良性浅表淋巴结节无论是病人还是健康人都会有【6-8】,利用弹性和B型超声双模态影像【6-7】、超声表常规超声特征及造影灌注【7】,以及超声引导下细针穿刺抽吸细胞学等方法,检查不同大、小颈部淋巴结的定性诊断,作为疾病风险分级诊断,评估良性淋巴结、淋巴瘤、反应性增生、淋巴结结核等等,淋巴结性质诊断疾病具有重要价值【10】。淋巴结肿大是淋巴内部的细胞增生或肿瘤细胞侵润而体积增大,常见病因是炎症(筋膜炎【11-12】、肿瘤疾病【13-14】、白血病【15】,各种癌症等肾透明细胞癌【16】、胃癌【17】、鼻咽癌【18】。
淋巴结与经络的相关性尚未报道,经络是中华医学之瑰宝,中医认为经络是运行全身精、气、血、津液【19】,经络的物质基础被认为是细胞产生Ca2+离子振荡幅频信号参与人体生命过程,调控人体经络网络的信息,在经线上的细胞缝隙连接蛋白(connexon),构成了经络的物质基础【20】。57鼻咽癌与217例健康人群对照研究存在着特征性经络改变【21】。乳腺癌与经络的运行变化密切相关,从经络的观点认为不通成结块,最终导致乳腺癌【22】。经络与胚胎发育异常及智力障碍综合征的特征之间存在惊人的对应关系【23】。带状疱疹有鲜明的临床经络证候特点【24】。2型糖尿病(T2DM)住院患者背俞穴有包括结节等不同的表现,肾俞阳性反应与血糖呈正相关(P<0.05)【25】。利用数据挖掘穴位按摩治疗失眠效果明显【26】。药物对穴位有不同的影响【27】。
经络作为中医外治法的主要理论基础,在透皮给药中常采用芳香开窍、活血化瘀治疗,有利于透皮给药皮肤吸收【28】。透皮给药具有安全、没有肝脏首过作用,并且方便、简单和药效持久。施用方法包括多肽透皮给药【29】、透皮纳米制剂【30】、复合透明质酸微针透皮给药【31】、喷雾透皮【32】、精油透皮给药【33】,通过对几种挥发油对黄藤素透皮给药的促渗作用研究表明,不同挥发油对皮肤的特征峰具有不同的影响,促渗能力较好的挥发油使皮肤的特征峰消失来增强皮肤对药物的渗透特色精油可作为透皮给药的理想促渗剂而具有广泛的应用前景。
参考文献
【1】韦红梅,高原驻训部队慢性疲劳综合征官兵的膳食调查,高原医学杂志,(2019)29(3)48
【2】Zhang Kaiyi;Lyu Zhengxuan;Liu Yongli;et al,A case of multisystemicdisseminated infection caused by Mycobacterium abscess diagnostic andtreatment process analysis,Chinese Journal of Antituberculosis,(2021)43(1)66-71
【3】Yang Xiaozhou;Yang Qingluan;Chen Yuming;et al,Analysis of clinicalcharacteristics and prognosis of Epstein-Barr virus-related diseases inadults,Chinese Journal of Infections Diseases,(2021)39(3)163-167
【4】Xu Feilong;Deng Xizi;Chen Xiejie;等.Clinical features of acquiredimmunodeficiency syndrome patients complicated with peripulmonaryoccupational lesions,Chinese Journal of Infections Diseases,(2021)39(3)152-156
【5】Xu,Y Y;Sheng,Y;Wang,C;等,Three cases of congenital tuberculosis,Chinese journal of pediatrics,(2021)59(3)230-232
【6】Shi,Jie;Jiang,Jianwei;Chang,Wanying;等,Multi-class discriminationof lymphadenopathy by using dual-modal ultrasound radiomics with elastographyand B-mode ultrasound,Journal of biomedical engineering,(2019)36(6)957-963
【7】Zhang Xueyun;Nie Fang;Lyu Wenhao;等,CEUS in differential diagnosisof benign and malignant cervical lymph nodes with different size,ChineseJournal of Medical Imaging Technology,(2019)35(4)530-534
【8】尹亮;黄世明;林志春;等,F-FDG PET/CT在巨淋巴结增生症中的应用,中国医学影像学杂志(2018)26(2)117-119
【9】Lin Wenjin;Xue Ensheng;Lin Zhenhu;等,Preliminary study of themalignant risk classification system for cervical lymph node,Chinese Journalof Ultrasonography,(2021)30(2)126-131
[10]Jin Ya;Peng Yulan;Qiu Li;等,The Perfusion Pattern ofLymphadenopathy in Contrast-enhanced Ultrasonography under DifferentReference Conditions,Journal of Sichuan University.Medical Science Edition,(2014)45(6)1005-1009
【11】王萍萍;李奥;许迪,结节性筋膜炎伴骨破坏超声表现1例,临床超声医学杂志,(2021)23(3)219-219,225
【12】幼年特发性关节炎诊断及治疗-全身型幼年特发性关节炎发病机制研究进展
Chen Tongxin;Zhang Chenxing,Update on the pathogenesis of systemicjuvenile idiopathic arthritis,Chinese Journal of Practical Pediatrics,(2021)36(1)16-19
【13】徐红艳;黄慧;张守华;等,43例儿童淋巴瘤细针穿刺细胞病理学特征并文献复习,临床与实验病理学杂志,(2021)37(3)330-332
【14】平璐依;郭良云;刘燕娜,腮腺巨大腺淋巴瘤超声表现一例,中华医学超声杂志(电子版),(2021)18(1)118-119
【15】Zhu,Y M;Gao,Q Y;Hu,J;等,Clinical and laboratory analysis of 17patients with gammadeltaT-cell large granular lymphocyte leukemia,Zhonghuaxue ye xue za zhi,(2020)41(2)112-116
【16】Han Dong;Zhang Xirong;Jia Yongjun;等,A Neural Network Model Basedon Enhanced CT for Distinguishing ISUP Grade of Clear Cell Renal CellCarcinoma,Cancer Research on Prevention and Treatment,(2021)48(1)55-59
【17】Chai Yaru;Gao Jianbo;Yue Songwei;等,Application value of spectralCT multi-parameter imaging in predicting gastric cancer lymph nodemetastasis,Chinese Journal of Digestive Surgery,(2021)20(2)240-245
【18】孙付国;陈璐;周瑞豪;等,鼻咽癌早期疼痛1例分析,中国疼痛医学杂志,(2021)27(2)157-158
【19】张晓平,浅议经络本体,Journal of Traditional Chinese Medicine中医杂忐,(2013)54:9,801-803
【20】Deng Qinkai,Discrimination of Meridian EssenceResearch onMeridian Essenc and Its Bioequivalence经络实质辨析关于经络本质与生物学基础的研究,Chinese Journal of Medical Physics中国医学物理学杂志,(2004)21:2,63-66,72
【21】Lin Baorui,Zhou Xiaojun,Wei Fuyuan,He Xijun,Characteristics ofDeficiency and Excess on Meridians of Nasopharyngeal Carcinoma,鼻咽癌经络虚实特征研究,Chinese Journal of Basic Medicine in Traditional Chinese Medicine,中国中医基础医学杂忐,(2017)23:9,1272-1275
【22】叶凯,杨小娟,黄芊,吴红彦,窦建卫,乳腺癌之经络观,Chinese Journal ofBasic Medicine in Traditional Chinese Medicine中国中医基础医学杂志,(2018)24:2,168-169
【23】LiLing,Zhuang Yonglong,Zhang Kelan,Meridian phenomenon in thedevelopment of human embryo人体胚胎发育过程中的经络现象,Chinese Acupunctureand Moxibustion中国针灸,(2003)23:3,150-154
【24】周宇,张宁,带状疱疹临床经络证候特点分析,Chinese Journal of BasicMedicine in Traditional Chinese Medicine,中国中医基础医学杂志,(2010)16:9,812-813
【25】Du Yuewei,Chen Songhe,Gao Yanhua,Liu Changqing,Study on theregularity of back-shu point reaction point in type 2 diabetes mellitusinpatients,2型糖尿病住院患者背俞穴反应点分布规律研究,China Journal ofTraditional Chinese Medicine and Pharmacy中华中医药杂志,(2021)36:2,1105-1108
【26】Huang Ruiying,Ma Xiaoqin,Yan Xinling,Analysis of dialecticalacupoint selection rules of acupoint massage in treatment of insomnia,穴位按摩治疗失眠的辩证选穴规律分析,Chinese Journal of Nursing,中华护理杂志,(2021)56:3,404-408
【27】Yan Suqing,Guo Jingke,Xu Mingming,Zhou Fang,Chen Luhang,WangQiang,Ke Lijing,Li Yubo,Rao Pingfan,Study on the Antioxidant Activity ofDendrobium officinale Kimura et Migo and Its Different Effects on Zang-FuOrgans Channel Tropism铁皮石斛的抗氧化性与其脏腑归经作用差异性的研究,ChineseJournal of Integrated Traditional and Western Medicine,中国中西医结合杂志,(2021)41:1,41-45
【28】隋毅,聂赞,经络学说与透皮给药系统,Chinese Journal of BasicMedicine in Traditional Chinese Medicine中国中医基础医学杂志,(2003)9:1,53-54
【29】李光强;吴丹丹;满玉清;等,多肽透皮给药研究进展,中国医院药学杂志,(2018)38(19)2084-2087
【30】胡胜涛;张二兵;林也;等,经皮给药纳米载体及靶向系统治疗类风湿关节炎研究进展,中国生物工程杂志,(2021)41(2/3)98-106
【31】余伟江;江国华,透明质酸/海藻酸钠复合微针的制备及胰岛素透皮给药研究,中国化学会2017全国高分子学术论文报告会摘要集——主题G:药物控释载体高分子
【32】卢望丁;罗华菲;王浩,定量透皮喷雾系统在透皮给药中的应用,世界临床药物,(2014)35(4)245-249
【33】赵茜;李伟泽;程玉钏;等,几种挥发油对黄藤素透皮给药的促渗作用研究,应用化工,(2016)45(1)186-189
【34】Gang Wang,a,b Qian Si,a,b Shurong Yang,et al.Lactic acid bacteriareduce diabetes symptoms in mice by alleviating gut microbiota dysbiosis andinflammation in different manners,Food Funct.(2020)11,5898-5914.
【35】Shibin Zhou,Claudia Gravekamp,David Bermudes,et al.Tumor-targeting bacteria engineered to fight cancer,Nat Rev Cancer(2018)volume 18,pages727-743
【36】Mai Thi-Quynh Duong,Yeshan Qin,Sung-Hwan You,et al.Bacteria-cancer interactions:bacteria-based cancer therapy,Experimental&MolecularMedicine(2019)51:152
【37】Silvia Vivarelli,Rossella Salemi,Saverio Candido,et al.GutMicrobiota and Cancer:From Pathogenesis to Therapy,Cancers(2019)11,38.
【38】Zehra Esra Ilhan;Melissa M.Herbst-Kralovetz.Themicrobiome and gynaecoiogical cancer development,prevention and therapy[J].Nature Reviews Urology,2020,17(4):232-250.
【39】Muhammad Sohail Khan,Muhammad Ikram,Jun Sung Park,et al.GutMicrobiota,Its Role in Induction of Alzheimer’s Disease Pathology,andPossible Therapeutic Interventions:Special Focus on Anthocyanins.
Cells(2020)9,853;doi:10.3390/cells9040853
发明内容
1、一种益菌药肽精华透皮给药及简易按摩器按摩经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经的技术与产品制备。本技术包括主料、辅料、药肽精华的配制及比例,以及透皮给药按摩方法。主料是中药抽提物;辅料是精油或者粘稠润滑的精华液,形成药肽精华,通过按摩经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、散结消炎、风湿痹痛、活血调经。
2、透皮药肽主料中药组成成分。中药根据不同需求可加入多味中药,常用的包括蒲公英、当归、牛蒡根、玫瑰花、连翘、甘草、红景天、红花、葛根、三七、鸡血藤、夏枯草、生姜、伸筋草、虎杖、金银花和菊花等等提取物和肽,根据不同要求,可以加入任何其他中药成分或者抽提物,任何一种或者多种按一定比例配制而成。传统功能具有:消炎散结、护肤养颜、去黄褐斑、活血通络、月经不调、消肿定痛、目赤清热、柔肝理肺、热毒痈肿、疔毒疮肿。
表1药肽精油成分具体功能
常用的中药主料比例为(100%):
(1)蒲公英设定使用比例0%至20%。
(2)当归设定使用比例0%至20%。
(3)牛蒡根设定使用比例0%至20%。
(4)玫瑰花设定使用比例0%至20%。
(5)红花设定使用比例0%至20%。
(6)葛根设定使用比例0%至20%。
(7)三七设定使用比例0%至20%。
(8)鸡血藤设定使用比例0%至20%。
(9)夏枯草设定使用比例0%至20%。
(10)连翘设定使用比例0%至20%。
(11)甘草设定使用比例0%至20%。
(12)伸筋草设定使用比例0%至20%。
(13)虎杖设定使用比例0%至20%。
(14)金银花设定使用比例0%至20%。
(15)菊花设定使用比例0%至20%。
(16)红景天设定使用比例0%至20%。
(17)生姜设定使用比例0%至20%。
(18)肽设定使用比例0%至20%。
3、益菌药肽微生物发酵方法
用乳酸菌、双歧杆菌、纳豆芽孢杆菌、地衣芽孢杆菌等菌液浸泡中药主料,发酵中药后提取发酵物,取上清液,灭菌,备用。
4、药肽的中药成分精油萃取方法、水以及酒精提取方法。抽提方法可以根据根据辅料要求,有精油萃取、水及酒精抽提方法。
(1)精油中药萃取方法
将精油慢慢加入中药中没过中药后,文火加热,至沸腾停止加热,慢慢冷凝后加入等体积过滤水,再次加热,至沸腾,停止加热,室温冷却,抽提3-48小时,过滤取精油备用。
(2)水抽提方法
将水慢慢加入中药中没过中药后,文火加热,至沸腾停止加热,慢慢冷凝室温冷却,抽提1-48小时,过滤取精油备用。
(3)酒精抽提方法
将55%-100%慢慢加入中药中没过中药后,室温静止,抽提5-48小时,过滤取精油备用。
5、透皮给药舒筋活络药肽,包括通用型及益目型、妇科型、清火型等等,阐述了透皮给药各种类型主料提取物最佳使用比例:
(1)通用型各种舒筋活络主料提取物可以单独或者复合使用,最佳使用比例(100%):
①蒲公英提取物使用比例10%。
②川穹提取物使用比例10%。
③当归提取物使用比例5%。
④牛蒡根提取物使用比例5%。
⑤玫瑰花提取物使用比例5%。
⑥红花提取物使用比例5%。
⑦葛根提取物使用比例5%。
⑧三七提取物使用比例5%。
⑨鸡血藤提取物使用比例5%。
⑩夏枯草提取物使用比例5%。
(2)醒目型舒筋活络主料提取物可以单独或者复合使用,最佳使用比例(100%):
①蒲公英提取物使用比例40%。
②川穹提取物使用比例30%。
③夏枯草提取物使用比例30%。
④肽使用比例30%。
(3)妇科型舒筋活络主料提取物可以单独或者复合使用,最佳使用比例(100%):
①蒲公英提取物使用比例10%。
②川穹提取物使用比例10%。
③当归提取物使用比例10%。
④玫瑰花提取物使用比例10%。
⑤三七提取物使用比例10%。
⑥鸡血藤提取物使用比例10%。
⑦生姜提取物使用比例10%。
⑧肽使用比例20%。
(4)清火型各种主料提取物可以单独或者复合使用,最佳使用比例(100%):
①蒲公英提取物使用比例20%。
②当归提取物使用比例20%。
③牛蒡根提取物使用比例10%。
④甘草提取物使用比例10%。
⑤肽使用比例20%。
上述比例可以根据不同患者需求,自行修改变动,并可以加入其他相关中药。
6、透皮给药的药肽精华辅料(两类:精油和精华液)
透皮给药的药肽精华辅料有两类:精油类和水溶性精华液
(1)精油可以用任何植物、动物油脂为基础油,通过实验发现,霍霍巴油和葡萄籽油作为基础油较为适宜,与中药精油萃取油以:中药精油萃取油∶基础油=1∶0-100的比例皆可。对于没有特别严重病变的人员,最佳比例为1∶50。
(2)水溶性精华液:最佳是“食妙蓉”精华液。中药发酵提取物∶精华液=1∶0-100的比例皆可。对于没有特别严重病变的人员,最佳比例为1∶50。
(3)配好主料和辅料后,可以直接进行按摩和透皮给药,也可以放入滚珠瓶中进行按摩透皮给药,方法如下。
7、透皮给药去结节疏通经络和淋巴治疗偏头痛方法,以滚珠瓶子作为小型按摩器,或者用手按推拿走向分为3条:(1)由神庭经百会、风府穴到大椎穴;(2)由头维穴经下关向颈部按摩,尤其是颈中咽侧淋巴结、锁骨上淋巴结等至云门穴、气户穴;(3)轻按太阳穴,经耳上各个穴位下至风池穴,顺着穴位点,推拿耳后淋巴结、颈后三角淋巴结,至肩井穴。治疗关节痛以及体表结节,首先针对痛点及相关穴位进行按摩、涂药治疗,通过透皮给药,对关节痛和体表结节等有一定作用。
8、本益菌药肽精华透皮给药,可以在人体任何外皮肤中利用,如四肢、关节、腿部、脚部、腹部和背部,以去结节疏通经络和淋巴除治疗偏头痛、关节痛、散结消炎、风湿痹痛、活血调经外,还能够治疗、风湿痹痛、散结消肿。
9、益菌药肽精华透皮给药产品,可以制备成液体涂用,也可以制备成创可贴式,浸在止血棉垫中,用医用胶带贴于脚心、关节和外表皮需要处。
具体实施方式
实施例1
益菌药肽精华透皮给药去结节疏通经络和淋巴治疗偏头痛、关节痛、散结消炎、风湿痹痛、活血调经活血调经,通过主料、辅料、小型按摩器载体以及手法,使遍布儿童、青年、中年和老年的压力型偏头痛治愈,统计了对113名大学生,100%都发生过偏头痛,尤其在期中、期末考试期间。压力型偏头痛发病通常因素有高度集中精力、用脑过度、熬夜、精神压力大、神经衰弱和焦虑,严重影响睡眠质量,因为睡眠不足,又形成偏头痛的恶行循环。偏头痛经常发作导致性格发生变化,往往性情变得暴躁,心理、生活和社会关系受到重大影响。
应用本技术方法,10分钟左右的按摩和换环境舒缓,基本治愈了压力型偏头痛,避免偏头痛的发作,以减少对学习、生活和工作的影响。
实施例2
透皮药肽主料中药组成成分及制备方法。中药根据不同需求可加入多味中药,常用的包括蒲公英、当归、牛蒡根、玫瑰花、连翘、甘草、红景天、红花、葛根、三七、鸡血藤、夏枯草、生姜、伸筋草、虎杖、金银花和菊花等等提取物和肽,根据不同要求,可以加入任何其他中药成分或者抽提物,任何一种或者多种按一定比例配制而成。传统功能具有:消炎散结、护肤养颜,去黄褐斑,活血通络,月经不调;消肿定痛、目赤清热、柔肝理肺,热毒痈肿、疔毒疮肿。上述常用的中药主料比例为0%至20%。
采取益菌药肽微生物发酵方法,用乳酸菌、双歧杆菌、纳豆芽孢杆菌、地衣芽孢杆菌等等菌液浸泡中药主料,发酵中药后提取发酵物,取上清液,灭菌,备用。药肽的中药成分精油萃取方法、水以及酒精提取方法。抽提方法可以根据根据辅料要求,有精油萃取、水及酒精抽提方法。
实施例3
功能型舒筋活络通用型及益目、妇科、清火型透皮给药各种主料提取物最佳使用比例(100%):通用型各种舒筋活络主料采用15种中药提取物,也可以根据不同的组配形成不同的组合,佳使用比例见说明书5(1)。通用型各种舒筋活络主料采用15种中药提取物,也可以根据不同的组配形成不同的组合,佳使用比例见说明书5(2)。醒目型舒筋活络主料采用4种中药提取物,并可以根据不同的要求添加更多的中药成分,佳使用比例见说明书5(3)。妇科型舒筋活络主料采用8种中药提取物,并可以根据不同的要求添加更多的中药成分,佳使用比例见说明书5(4)。妇科型舒筋活络主料采用5种中药提取物,并可以根据不同的要求添加更多的中药成分,佳使用比例见说明书5(5)。上述比例可以根据不同患者需求,自行修改变动,并可以加入其他相关中药。
可以直接用功能型舒筋活络通用型及益目、妇科、清火型透皮给药各种主料进行透皮给药,在人体任何外皮肤中利用,如四肢、关节、腿部、脚部、腹部和背部,以去结节疏通经络和淋巴治疗偏头痛、关节痛、散结消炎、风湿痹痛、活血调经、风湿痹痛、散结消肿。
也可以形成益菌药肽精华透皮给药产品,制备成液体涂用,也可以制备成创可贴式,浸在止血棉垫中,用医用胶带贴于脚心、关节和外表皮需要处,以治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经等等。
实施例4
益菌药肽精华透皮给药的药肽精华辅料的制备及益菌药肽精华的制备,辅料有两类:精油类和水溶性精华液。
精油类可以用任何植物、动物油脂为基础油,通过实验发现,霍霍巴油和葡萄籽油作为基础油较为适宜,与中药精油萃取油以:中药精油萃取油∶基础油=1∶0-100的比例皆可。对于没有特别严重病变的人员,最佳比例为1∶50。
水溶性精华液:最佳是“食妙蓉”精华液。中药发酵提取物∶精华液=1∶0-100的比例皆可。对于没有特别严重病变的人员,最佳比例为1∶50。
实施例5
透皮给药推拿淋巴与经络的感知及对偏头痛的治疗。配好主料和辅料后,可以直接用按摩方法进行人手按摩透皮给药,也可以放入滚珠瓶中进行按摩透皮给药,以通过透皮给药去结节疏通经络和淋巴治疗偏头痛,具体方法为:先涂好药肽精华用人手和肘按摩,或者以滚珠瓶子(瓶中装有药肽精华)作为小型按摩器进行推拿按摩,走向分为3条:(1)由神庭经百会、风府穴到大椎穴;(2)由头维穴经下关向颈部按摩,尤其是颈中咽侧淋巴结、锁骨上淋巴结等至云门穴、气户穴;(3)轻按太阳穴,经耳上各个穴位下至风池穴,顺着穴位点,推拿耳后淋巴结、颈后三角淋巴结,至肩井穴。
利用药肽精油,做3个方向的穴位群推拿有明显的体液流动感知,能很好地改善压力型偏头痛。如当按摩推拿右侧经络时,明显感到有浅表淋巴管液或者经络“涨、酥、麻”的流向感知。像淋巴管或者经络管道中有液流向固定的方向输送,又像慢慢的电流,推拿到一定程度时,明显感到的液体的流动走向,但是,这种感觉维持时间比较短大约2-3秒钟。这种感觉出现在按摩的第二阶段,如果将按摩感知分为三个阶段。
第一阶段按摩导致按压穴位点或者淋巴周边组织非常痛,中医经络认为是痛点,经络不通,需要配合性深呼吸;第二阶段出现“涨、酥、麻”的体液流动感觉,有明显的体液在几个管道内按一定方向流动的感知,具体走向与经络和淋巴管相辅相成,尤其是有淋巴管的地方如腋下、胸部的液体按4个固定的方向流动:手太阴肺经的1、由云门穴向中府穴;2、由云门穴经天府穴、侠白、至尺泽穴。3、足阳明胃经中由气户至鹰窗。4、足少阳胆经的肩井穴至渊腋穴。第三阶段继续按压液体流向的感觉消失。
推拿后淋巴结结节很快软化变小(见表2),甚至用手抚摸查找不到原来的淋巴结结节了。淋巴结变小变软后,偏头痛症状明显消失,且耐受了长时间熬夜对偏头痛的影响和关联性,药肽精油颈部浅表淋巴结和经络推拿方法,减少了压力型偏头痛症状。
实施例6
颈部浅表淋巴结的散结与偏头痛的消除相关性
淋巴结结节的存在与偏头痛正相关,偏头痛常伴有淋巴结肿大【1】。发明人因工作压力偏头痛、右侧上、下牙全部持续牙痛2个月,导致颈部右侧淋巴结持续肿胀,包括右侧下颌下淋巴结、颈中咽侧淋巴结、颈后三角淋巴结、耳后淋巴结、枕后淋巴结、锁骨上淋巴结,仔细抚摸能够发现较硬淋巴结。尤其是右侧颈后三角淋巴结和颈中咽侧淋巴结较大,(见表1)大小为0.6X0.5cm,其他淋巴结为0.5X0.5左右。
表2经络按摩后浅表淋巴结的变化
对有偏头痛史的113人进行了颈后三角淋巴结、耳后淋巴结、锁骨上淋巴结的淋巴结结节统计(见表3),大多数人头疼症状消失或者轻微时,淋巴结节不明显,就是淋巴结处用手揉按没有明显硬结者,视为“无”。而有些经常偏头痛却没有进行任何治疗者,按淋巴结处手感有明显硬结,视为者为“有”;统计表明颈部浅表淋巴结与偏头痛呈现明显正相关。
表3压力偏头痛113位病史人员的4个颈部浅表淋巴结统计结果
经过利用药肽精油的经络推拿后淋巴结明显变小变软(见表2),偏头痛症状明显消失,在15天期间即使熬夜也没有偏头痛发作。
实施例8
益菌药肽微生物发酵过程中,用乳酸菌、双歧杆菌、纳豆芽孢杆菌、地衣芽孢杆菌等菌液浸泡中药主料,发酵中药提取发酵物后,废弃物经取上清液,灭菌,还发现其他功效:
(1)消化系统不适:具有调节肠道菌群、缓解功能性胃肠道疾病的功能。
(2)胃炎:对幽门螺杆菌有强抑制作用,对胃癌的生物致病菌具有良好的抑制效果。
(3)肠炎:利于成人、患儿肠炎正常胃肠功能的恢复以及免疫功能的提升。
(4)便秘:辅助治疗功能性便秘。
(5)尿酸:本品含有大量天然提取物、益生菌、蛋白酶解物及多肽等活性物质,有降尿酸作用。
(6)秘尿系统:预防尿路感染细菌性阴道炎的反复发作。
Claims (10)
1.一种益菌药肽精华透皮给药,通过透皮给药按摩去结节疏通经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经的技术与产品制备。本技术包括应用主料、辅料配制益菌药肽精华,通过小型按摩滚珠瓶或者手肘按摩透皮给药的方法进行。主料是中药抽提物;辅料是精油或者粘稠润滑的精华液,组合在一起形成药肽精华以便透皮给药:通过药肽精华按摩经络和淋巴治疗偏头痛、关节痛,以及体表结节、散淤消炎、风湿痹痛、活血调经。
2.根据权利要求1所述透皮药肽主料中药组成成分及比例。中药根据不同需求可加入多味中药,常用的包括蒲公英、当归、牛蒡根、玫瑰花、连翘、甘草、红景天、红花、葛根、三七、鸡血藤、夏枯草、生姜、伸筋草、虎杖、金银花和菊花等等提取物和肽,根据不同要求,可以加入任何其他中药成分或者抽提物,任何一种或者多种按一定比例配制而成。传统功能具有:消炎散结、护肤养颜、去黄褐斑、活血通络、月经不调、消肿定痛、目赤清热、柔肝理肺、热毒痈肿、疔毒疮肿。
3.根据权利要求1所述益菌药肽需要微生物发酵的方法,用乳酸菌、双歧杆菌、纳豆芽孢杆菌、地衣芽孢杆菌等菌液浸泡中药主料,发酵中药后提取发酵物。
4.根据权利要求1所述益菌药肽的中主料的中药成分的提取,根据使用要求有精油、水以及酒精等三种提取方法。
5.根据权利要求1所述透皮给药舒筋活络益菌药肽从功能上可分列组合成四类,包括通用型、益目型、妇科型及清火型等等,阐述了透皮给药各种类型主料提取物最佳使用比例。可以根据不同患者需求,自行突出重点略改中药比例,并可以加入其他相关中药。
6.根据权利要求1所述透皮给药的药肽精华的两类辅料,包括精油类和水溶性精华液类,及其配制成品使用比例。
7.根据权利要求1所述透皮给药去结节疏通经络和淋巴治疗偏头痛方法,以滚珠瓶子作为小型按摩器,或者用手按推拿走向分为3条:(1)由神庭经百会、风府穴到大椎穴;(2)由头维穴经下关向颈部按摩,尤其是颈中咽侧淋巴结、锁骨上淋巴结等至云门穴、气户穴;(3)轻按太阳穴,经耳上各个穴位下至风池穴,顺着穴位点,推拿耳后淋巴结、颈后三角淋巴结,至肩井穴。治疗关节痛这对痛点关节相关的穴位进行按摩治疗。
8.根据权利要求1所述本益菌药肽精华透皮给药,可以在人体任何外皮肤中利用,如四肢、关节、腿部、脚部、腹部和背部,以去结节疏通经络和淋巴除治疗偏头痛、关节痛、散结消炎、风湿痹痛、活血调经外,还能够治疗、风湿痹痛、散结消肿。
9.根据权利要求1所述益菌药肽精华透皮给药产品,可以制备成液体涂用,也可以制备成创可贴式,浸在止血棉垫中,用医用胶带贴于脚心、关节和外表皮需要处。
10.益菌药肽微生物发酵过程中,用乳酸菌、双歧杆菌、纳豆芽孢杆菌、地衣芽孢杆菌和枯草芽孢杆菌等菌液浸泡中药主料,发酵中药提取发酵物后,废弃物经取上清液,灭菌,后还可以治疗消化系统不适、胃炎、肠炎、便秘、尿酸、预防尿路感染细菌性阴道炎的反复发作。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110986029.1A CN113813359A (zh) | 2021-08-22 | 2021-08-22 | 益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110986029.1A CN113813359A (zh) | 2021-08-22 | 2021-08-22 | 益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113813359A true CN113813359A (zh) | 2021-12-21 |
Family
ID=78913614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110986029.1A Pending CN113813359A (zh) | 2021-08-22 | 2021-08-22 | 益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113813359A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737769A (zh) * | 2022-11-24 | 2023-03-07 | 周国莉 | 一种用于治疗肺结节的给药套装 |
CN116211982A (zh) * | 2023-01-17 | 2023-06-06 | 上海市普陀区中心医院 | 一种治疗中低危肺部结节的复方制剂、制备方法及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904977A (zh) * | 2010-08-27 | 2010-12-08 | 葛德钜 | 一种治疗乳腺炎的药物及其制备方法 |
CN109568393A (zh) * | 2018-12-25 | 2019-04-05 | 合肥卡迪尔生物科技有限公司 | 一种中药按摩精油及其制备方法 |
CN112494606A (zh) * | 2019-09-15 | 2021-03-16 | 赵文左 | 治疗筋骨、风湿类疼痛的中药组合物及其制备方法和应用 |
-
2021
- 2021-08-22 CN CN202110986029.1A patent/CN113813359A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101904977A (zh) * | 2010-08-27 | 2010-12-08 | 葛德钜 | 一种治疗乳腺炎的药物及其制备方法 |
CN109568393A (zh) * | 2018-12-25 | 2019-04-05 | 合肥卡迪尔生物科技有限公司 | 一种中药按摩精油及其制备方法 |
CN112494606A (zh) * | 2019-09-15 | 2021-03-16 | 赵文左 | 治疗筋骨、风湿类疼痛的中药组合物及其制备方法和应用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737769A (zh) * | 2022-11-24 | 2023-03-07 | 周国莉 | 一种用于治疗肺结节的给药套装 |
CN116211982A (zh) * | 2023-01-17 | 2023-06-06 | 上海市普陀区中心医院 | 一种治疗中低危肺部结节的复方制剂、制备方法及用途 |
CN116211982B (zh) * | 2023-01-17 | 2023-12-12 | 上海市普陀区中心医院 | 一种治疗中低危肺部结节的复方制剂、制备方法及用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101214286B (zh) | 一种有效治疗风湿性疼痛病的中药白酒制剂 | |
CN113813359A (zh) | 益菌药肽疏经络通淋巴透皮给药治疗偏头痛、关节痛、散结消炎的技术与产品制备 | |
CN103316315B (zh) | 一种退热贴 | |
CN102824445A (zh) | 一种治疗十二指肠溃疡的中药组合物 | |
CN1583001A (zh) | 红外止咳贴 | |
CN102755515B (zh) | 治疗乳腺增生的中药汤剂 | |
CN105326926B (zh) | 一种治疗经筋疾病的外用药物制剂、其制备方法和应用 | |
CN104352856B (zh) | 一种治疗复发性口腔溃疡的中药组合物 | |
CN1698736A (zh) | 治疗乳腺增生、预防乳腺癌的外用药 | |
CN109078162A (zh) | 一种防治鼻癌的生物配制方法 | |
CN101732425B (zh) | 一种牛皮癣外用药组合物 | |
CN110478418A (zh) | 一种镇痛生肌的擦剂 | |
CN1765381A (zh) | 一种调理补气溶脂膏 | |
CN102895414B (zh) | 一种治疗浅表类型癌症的中药膏 | |
CN103720893B (zh) | 一种治疗颈椎病的中草药配方及其制备方法 | |
CN102961689B (zh) | 一种治疗慢性胆囊炎或胆石症的中药制剂 | |
CN103893332A (zh) | 一种治疗胃炎的中药 | |
CN105267683A (zh) | 一种治疗阴虚毒恋型肛门直肠周围脓肿的中药制剂 | |
CN111671862A (zh) | 一种治疗恶性肿瘤的中药复方制剂及其制备方法 | |
CN105381098A (zh) | 一种治疗膝骨性关节炎的中药熏洗剂及护理方法 | |
CN104524284A (zh) | 防治流感的药物 | |
CN115487261A (zh) | 一种用于治疗风湿骨痛疮痈肿毒的药酒及其制备方法 | |
CN111632123A (zh) | 一种健脾脐贴药剂 | |
CN103349720A (zh) | 一种治疗急性膀胱炎的中药组合物 | |
CN102949594A (zh) | 用于治疗胃病的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211221 |